The role of histone lysine methyltransferase NSD3 in cancer

Xu Han1,* Lianhua Piao2,* Qianfeng Zhuang1 Xiaofeng Yuan3 Zhiwei Liu3 Xiaozhou He1

1Department of Urology, The Third Affiliated Hospital of Soochow University, 2Institute of Bioinformatics and Medical Engineering, Jiangsu University of Technology, 3Department of Orthopaedics, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, People’s Republic of China

*These authors contributed equally to this work

Abstract: The growing number of findings demonstrate that nuclear receptor suppressor of variegation, enhancer of zeste, and trithorax domain-containing 3 (NSD3) is amplified and overexpressed in multiple cancer types. Nevertheless, the biological roles of NSD3 in carcinogenesis have not been well understood. In this review, we summarize the current knowledge on the mechanisms underlying NSD3 regulation in different cancers. In addition, NSD3 may serve as a potential druggable target for selective cancer therapy in the future.

Keywords: NSD3, cancer, carcinogenesis

Introduction

Nuclear receptor suppressor of variegation, enhancer of zeste, and trithorax (SET) domain-containing 3 (NSD3) is a well-known histone lysine methyltransferase (HMTase), a member of the NSD protein family. This family is composed of three HMTases, such as NSD1, NSD2 (WHSC1/MMSET), and NSD3 (Wolf–Hirschhorn syndrome candidate 1-like 1 [WHSC1L1]), which are primarily known to be involved in chromatin integrity and gene expression through mono-, di-, or tri-methylating lysine 36 of histone H3 (H3K36), respectively.1–3

Accumulating evidence reveals that the amplification of NSDs results in cellular transformation and plays crucial roles in cancer pathogenesis.4 Herein, we review the fundamental characteristics of the third member NSD3, with particular focus on the biological functions of NSD3 in a great variety of cancers (Table 1). Notably, NSD3 contributes to tumorigenesis by interacting with bromodomain-containing protein 4 (BRD4), the bromodomain and extraterminal (BET) protein, which is a potential therapeutic target in acute myeloid leukemia (AML).

Identification and characterization of NSD3

NSD3, also known as WHSC1L1, is originally identified in 2001.5,6 Similar to NSD1 and NSD2, the NSD3 gene also possesses a C-terminal block containing ~700 amino acids. Nonetheless, the conserved PHD5–C5HCH module of NSD3 prefers to recognize and bind to the N-terminal peptides of histone H3, such as unmodified K4 and tri-methylated K9, which is greatly different from the other two members.7 Importantly, the NSD3 gene is located on chromosome 8p11.23, along with strong cancer relevance. A total of three protein products of NSD3 deserve to be reported and characterized as long, short, and whistle (Figure 1).8

The NSD3-long isoform encodes a protein of 1,437 amino acids, which contains two proline-tryptophan-tryptophan-proline (PWWP, the conserved motif Pro–Trp–Trp–Pro) domains, five plant homeo domain (PHD)-type zinc finger motifs, one SET-associated
Cys (SAC)-rich domain, and one SET domain. Notably, the C-terminal of NSD3-long isoform, which contains the pre-SET, SET, and post-SET domains within the catalytic core, is critical for its recognizing and methylating molecular targets of histones H3 and H4 in vitro.\(^9,10\)

Compared with NSD3-long isoform, the NSD3-short isoform encodes a 645-amino acid protein that lacks the catalytic SET domain, but it reserves one N-terminal PWWP domain of 620 amino acids, which can bind to histone H3 at lysine 36.\(^11,12\) Interestingly, both transcripts of NSD3-short and NSD3-long isoforms are coexpressed in tumorous tissues, which mean that they have to compete for protein interaction via the analogous PWWP domain.

Whistle (WHSC1-like 1 isoform 9 with methyltransferase activity to lysine) is the shortest isoform of NSD3 and merely consists of 506 amino acids, which retains the following three distinct domains: PWWP, SET, and post-SET. NSD3-whistle is capable of repressing gene transcription by facilitating specific di-methylation activities on histones H3K4 and H3K27.\(^13\)

### NSD3 in AML

The NSD3 gene has been observed as a transcriptional coactivator in prior analyses of some cases with AML. Rosati et al\(^{14}\) first reported that there is a fusion between the NUP98 and NSD3 genes in a patient accompanied with t(8;11)

<table>
<thead>
<tr>
<th>Associated cancer</th>
<th>Alteration in cancer</th>
<th>Pathways</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute myeloid leukemia</td>
<td>NUP98–NSD3 fusion(^{14,15}) or NSD3–BRD4–CHD8 fusion(^{16})</td>
<td>Cell cycle progression by E2F2, ER signaling, WNT signaling</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>Amplification(^{5,17,22})</td>
<td></td>
</tr>
<tr>
<td>NUT midline carcinoma</td>
<td>NSD3–NUT fusion(^{23,27})</td>
<td></td>
</tr>
<tr>
<td>Lung cancer</td>
<td>Amplification(^{28,29,30}) or BRD4–NSD3–MYC fusion(^{21})</td>
<td>Cell cycle progression by NEK7 and CCNG1</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>Amplification(^{30})</td>
<td>Cell cycle progression by NEK7 and CCNG1</td>
</tr>
<tr>
<td>Bladder cancer</td>
<td>Amplification(^{30})</td>
<td>Cell cycle progression by CDC6 and CDK2, EGFR/ERK signaling</td>
</tr>
<tr>
<td>Head and neck squamous cell carcinoma</td>
<td>Amplification(^{31,34})</td>
<td></td>
</tr>
<tr>
<td>Pelvic high-grade serous carcinoma</td>
<td>NSD3–BRD4–CHD8 fusion(^{15})</td>
<td></td>
</tr>
<tr>
<td>Osteosarcoma</td>
<td>Amplification(^{36})</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** BRD4, bromodomain-containing protein 4; CCNG1, cyclin G1; CHD8, chromodomain-helicase-DNA-binding protein 8; EGFR, epidermal growth factor receptor; ER, estrogen receptor; ERK, extracellular regulated protein kinases; NSD3, nuclear receptor SET domain-containing 3; NUT, nuclear protein in testis; SET, suppressor of variegation, enhancer of zeste, and trithorax; WNT, wingless int1.

### Table 1 Cancers associated with histone lysine methyltransferase NSD3

<table>
<thead>
<tr>
<th>Associated cancer</th>
<th>Alteration in cancer</th>
<th>Pathways</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute myeloid leukemia</td>
<td>NUP98–NSD3 fusion(^{14,15}) or NSD3–BRD4–CHD8 fusion(^{16})</td>
<td>Cell cycle progression by E2F2, ER signaling, WNT signaling</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>Amplification(^{5,17,22})</td>
<td></td>
</tr>
<tr>
<td>NUT midline carcinoma</td>
<td>NSD3–NUT fusion(^{23,27})</td>
<td></td>
</tr>
<tr>
<td>Lung cancer</td>
<td>Amplification(^{28,29,30}) or BRD4–NSD3–MYC fusion(^{21})</td>
<td>Cell cycle progression by NEK7 and CCNG1</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>Amplification(^{30})</td>
<td>Cell cycle progression by NEK7 and CCNG1</td>
</tr>
<tr>
<td>Bladder cancer</td>
<td>Amplification(^{30})</td>
<td>Cell cycle progression by CDC6 and CDK2, EGFR/ERK signaling</td>
</tr>
<tr>
<td>Head and neck squamous cell carcinoma</td>
<td>Amplification(^{31,34})</td>
<td></td>
</tr>
<tr>
<td>Pelvic high-grade serous carcinoma</td>
<td>NSD3–BRD4–CHD8 fusion(^{15})</td>
<td></td>
</tr>
<tr>
<td>Osteosarcoma</td>
<td>Amplification(^{36})</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** BRD4, bromodomain-containing protein 4; CCNG1, cyclin G1; CHD8, chromodomain-helicase-DNA-binding protein 8; EGFR, epidermal growth factor receptor; ER, estrogen receptor; ERK, extracellular regulated protein kinases; NSD3, nuclear receptor SET domain-containing 3; NUT, nuclear protein in testis; SET, suppressor of variegation, enhancer of zeste, and trithorax; WNT, wingless int1.

---

**Figure 1** Conserved structural domains of histone lysine methyltransferase NSD3.

**Note:** Colored shapes represent conserved domains in the proteins.

**Abbreviations:** NSD3, nuclear receptor SET domain-containing 3; PHD, plant homeo domain; PWWP, proline–tryptophan–tryptophan–proline; SET, suppressor of variegation, enhancer of zeste, and trithorax.
distinctly limited because of overexpressed NSD3. Moreover, functional differentiation in the mammary gland and developmental growth of the offspring are impaired by the decreased expression of a negative factor SFRP1. Remarkably, AML cells merely require the NSD3-short isoform, which lacks the catalytic SET domain, to allow transcriptional activation. Collectively, NSD3 can become a vital oncogene related to leukemogenesis when it is fused to NUP98 or bound to BRD4 and CHD8.

NSD3 in breast cancer

Angrand et al19 showed that NSD3 is amplified in primary tumors and cell lines from breast carcinoma. Zhou et al20 indicated that NSD3-long isoform may obviously suppress cell proliferation and invasion capacity through affecting the expression of cell cycle regulator E2F2. However, Yang et al21 found that knockdown of NSD3 via shRNA in breast cancer cells amplified 8p11-12 can dramatically inhibit cell growth and survival. The regulatory factors of WNT signaling, iroquois homeobox 3 (IRX3), and TBL1X are markedly promoted due to an enhanced expression of NSD3, accompanied by the decreased expression of a negative factor SFRP1. Irish et al22 confirmed that the overexpression of NSD3 in SUM-44 breast cancer cells is highly correlated with the overexpression of ESR1 mRNA and ERα protein, which are transcriptionally active in luminal breast cancer. In summary, these studies illustrate that NSD3 may be a candidate tumor suppressor or an activator in different genetic backgrounds. After analyzing the relationship between the NSD3 expression level and overall patient survival, Liu et al23 reported that higher expression patients have an HR of 1.659 compared with lower expression ones in breast cancer. Turner-Ivey et al24 observed that targeted expression of NSD3 in FVB mice develops mammary gland hyperplasias, dysplasias, carcinoma in situ, and mammary carcinomas by the age of 40 weeks. Moreover, functional differentiation in the mammary gland and developmental growth of the offspring are distinctly limited because of overexpressed NSD3. Aside from those experimental researches, Chen et al identified NSD3 as a bona fide transforming breast cancer oncogene through analyzing the gene amplifications in TCGA data sets derived from human specimens.22 Taken together, NSD3 is considered as a novel putative driving oncogene and a promising therapeutic approach in breast cancer patients.

NSD3 in nuclear protein in testis (NUT) midline carcinoma (NMC)

NMC is an exceedingly rare and poorly differentiated squamous cell carcinoma with a median survival of 6.7 months for the lack of standard treatment algorithms so far.25 It was reported that the NUT gene may fuse to NSD3 in NMC, which is known to typically harbor BRD4/3-NUT fusion oncoprotein. French et al26 showed that the protein encoded by NSD3–NUT fusion oncogene is necessary and sufficient for blocking differentiation and maintaining proliferation in NMC cells. Nevertheless, BET inhibitors, JQ1, are able to induce differentiation and arrest proliferation in 1,221 cells expressing NSD3–NUT fusion, which implies that NSD3–NUT complexes may need to utilize the chromatin-reading function of BRD4. Then, Kuroda et al first described the cytological features of lung NMC with the NSD3–NUT rearrangements and suggested that overt pearl formation including a dyskeratocyte, stratification, and cytoplasmic fine vacuoles is helpful to make a diagnosis of NMC.25,26 In addition, high levels of NUT are only unveiled in the undifferentiated NMC cells, but NUT expression is faint or absent in the keratinizing cells.27 Taking those into consideration, NSD3 is certainly a prominent part of the NSD3–NUT complexes triggering the oncogenesis of NMC.

NSD3 in lung, pancreatic, and bladder cancers

Coupling bioinformatics analysis with knockdown studies, Tonon et al28 identified NSD3 as a prime target of the 8p11-12 amplification event in both non-small cell lung cancer and pancreatic ductal adenocarcinoma. Mahmood et al29 further confirmed that NSD3 can promote the cell viability of small-cell lung cancer and pancreatic ductal adenocarcinoma both in anchorage-dependent and anchorage-independent conditions. Of note, the potential downstream genes targeted by NSD3 in these two cancer types are extraordinarily different from those in breast cancer. Kang et al30 indicated that the expression of NSD3 is significantly elevated in the tissues of lung adenocarcinoma and bladder cancer. After the depletion of NSD3, cell proliferation is effectively reduced and the expressions of cell cycle enhancers, cyclin G1 (CCNG1) and NEK7, are decreased via expression profile analysis, which imply that NSD3 appears to be a critical player in...
the G2/M transition. Besides, Li et al. uncovered another probable role of NSD3 in activating the oncogenic function of MYC gene by bridging MYC with BRD4 in lung cancer. The BRD4–NSD3–MYC pathway may be a newly therapeutic strategy, which successfully associates tumor activators with druggable targets. And in pancreatic adenocarcinoma, Mann et al. conducted a mutagenic screen using Sleeping Beauty (SB) in mice and showed that NSD3 can cooperate with oncogenic Kras to result in tumorigenesis, whereas the exact epigenetic mechanism of how dysregulation of NSD3 may lead to lung, pancreatic, and bladder cancers remains to be elucidated.

**NSD3 in squamous cell carcinoma of the head and neck (SCCHN), high-grade serous carcinoma (HGSC), and osteosarcoma**

Saloura et al. found that high NSD3 expression is implicated in poor grade and heavy smoking history in SCCHN. Furthermore, the transcription of cell cycle genes CDC6 and CDK2 contributing to the transition from G1 to S phase is directly modulated by the enhancement of H3K36 di-methylation. Later, they showed that NSD3 can mono-methylate lysine 721 of EGFR to promote activation of the extracellular regulated protein kinases cascade, which interacts with proliferating cell nuclear antigen to accelerate DNA replication and enhances cell cycle progression in SCCCHN cells. In pelvic HGSC of gynecological (tubo-ovarian or endometrial) origin, Jones and Lin insisted that the amplification of NSD3–BRD4–CHD8 axis is closely correlated with worse prognosis and survival compared with nonamplified cases, depending on the retrospective analysis of TCGA cancer cohorts. More recently, Liu et al. reported that silencing of NSD3 distinctly reduces cell viability and survival, along with increasing the percentage of cells in the G2/M phase and inducing cell apoptosis in osteosarcoma. In addition, 549 NSD3-regulated genes (244 upregulated and 305 downregulated) are identified via RNA-seq analysis. Hence, these data indicate that NSD3 possesses crucial effects in cell cycle progression.

**Conclusion and future perspective**

This review highlights the biological functions of NSD3 in a subset of cancers. Based on these findings, NSD3 is perceived mostly as an important adaptor protein to underline its indispensable part of oncogenic complexes. For instance, the NUP98–NSD3 fusion and the NSD3–NUT fusion are

![Figure 2](https://www.dovepress.com/)

**Figure 2** Schematic diagram of various cancers triggered by the associated NSD3 dysfunctions.

**Abbreviations:** AML, acute myeloid leukemia; BRD4, bromodomain-containing protein 4; CHD8, chromodomain-helicase-DNA-binding protein 8; HGSC, high-grade serous carcinoma; NMC, NUT midline carcinoma; NSD3, nuclear receptor SET domain-containing 3; NUP98, nuclear-pore-complex protein 98; NUT, nuclear protein in testis; SCCHN, squamous cell carcinoma of the head and neck; SET, suppressor of variegation, enhancer of zeste, and trithorax.
involved in chromatin remodeling and transcriptional regulation leading to oncogenesis. Also, the NSD3–BRD4–CHD8 axis and the BRD4–NSD3–MYC axis may sustain oncogenic transcriptional programs because their amplification is highly associated with worse overall survival and progression-free survival in patients. Besides, NSD3 can directly target different downstream genes that play central roles in various cellular processes (Figure 2).

As NSD3 may represent an effective and valuable target in the epigenetic therapy for patients with aberrant expression of HMTase, further investigation is urgently required to clarify the precise signaling pathways of NSD3 in cancer development and progression. Unfortunately, no inhibitors specifically targeting NSD3 have been found till date. However, in consideration of the BET inhibitors, JQ1, which have been applied in the clinical treatment of certain cancer, we believe that the inhibitors of NSD3 can offer newly promising therapeutic opportunities to cure and prevent human cancers in the near future.

Acknowledgments

This study was supported by the National Science Foundation of Jiangsu Province (grant no BK20150251) and Youth Medical Talent Project of Jiangsu Province (QNRC2016292).

Disclosure

The authors report no conflicts of interest in this work.

References


